Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
messenger RNA encoding human cytomegalovirus UL131A
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Messenger RNA encoding human cytomegalovirus UL131A is a specific mRNA component of Moderna's cytomegalovirus (CMV) vaccine candidate, mRNA-1647. It encodes the UL131A protein, which is one of the five subunits (along with gH, gL, UL128, and UL130) that form the CMV pentameric complex. This complex is essential for the virus's ability to infect epithelial, endothelial, and myeloid cells. When delivered via lipid nanoparticles, the mRNA is translated by host cells to produce the UL131A protein, which, in conjunction with the other vaccine-encoded subunits, triggers the production of neutralizing antibodies. mRNA-1647 is currently being evaluated in Phase 3 clinical trials (CMVictory study) for the prevention of primary CMV infection in women of childbearing age to prevent congenital CMV transmission.
- Other names
- UL131A mRNAUL-131A mRNAUL 131A mRNAmessenger RNA encoding human cytomegalovirus UL131A protein
02
Targets
HCMV surface antigens (Human cytomegalovirus surface antigens)
Beyond the preview
Go deeper on messenger RNA encoding human cytomegalovirus UL131A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on messenger RNA encoding human cytomegalovirus UL131A.